Regen BioPharma Inc (RGBP) stock
RGBPOTCPharmaceutical PreparationsFiscal year ends September 30Also trades as RGBPP
$0.00+0.00 (+50.00%)
Close on Oct 19, 2026Market cap $92.33KP/E –Yield –
Regen BioPharma profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Regen BioPharma's profit margin for the twelve months ending Jun 30, 2026 was -501.4%. For fiscal 2025 it was -538.8%, against -282.5% the year before. The highest annual figure on record is 3104.0% in fiscal 2020.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | -538.8% | −256.3 |
| FY2024 | Sep 30, 2024 | -282.5% | −771.4 |
| FY2023 | Sep 30, 2023 | 488.9% | −1457.9 |
| FY2022 | Sep 30, 2022 | 1946.8% | +13002.2 |
| FY2021 | Sep 30, 2021 | -11055.4% | −14159.4 |
| FY2020 | Sep 30, 2020 | 3104.0% | +5488.7 |
| FY2019 | Sep 30, 2019 | -2384.7% | +2330.5 |
| FY2018 | Sep 30, 2018 | -4715.2% | +593.0 |
| FY2017 | Sep 30, 2017 | -5308.2% | +2442.4 |
| FY2016 | Sep 30, 2016 | -7750.6% | −1919.8 |
| FY2015 | Sep 30, 2015 | -5830.8% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026CQ2 2026 | Jun 30, 2026 | -1079.8% | −796.6 |
| Q2 FY2026CQ1 2026 | Mar 31, 2026 | 1679.4% | +1712.1 |
| Q1 FY2026CQ4 2025 | Dec 31, 2025 | -1638.6% | −766.1 |
| Q4 FY2025CQ3 2025 | Sep 30, 2025 | -964.3% | −508.2 |
| Q3 FY2025CQ2 2025 | Jun 30, 2025 | -283.2% | −62.9 |
| Q2 FY2025CQ1 2025 | Mar 31, 2025 | -32.8% | +174.6 |
| Q1 FY2025CQ4 2024 | Dec 31, 2024 | -872.6% | −627.2 |
| Q4 FY2024CQ3 2024 | Sep 30, 2024 | -456.1% | +91.4 |
| Q3 FY2024CQ2 2024 | Jun 30, 2024 | -220.3% | −52.3 |
| Q2 FY2024CQ1 2024 | Mar 31, 2024 | -207.3% | −33.6 |
| Q1 FY2024CQ4 2023 | Dec 31, 2023 | -245.4% | −5415.2 |
| Q4 FY2023CQ3 2023 | Sep 30, 2023 | -547.5% | −300.9 |
| Q3 FY2023CQ2 2023 | Jun 30, 2023 | -168.0% | −214146.5 |
| Q2 FY2023CQ1 2023 | Mar 31, 2023 | -173.8% | +216603.1 |
| Q1 FY2023CQ4 2022 | Dec 31, 2022 | 5169.8% | −3189.8 |
| Q4 FY2022CQ3 2022 | Sep 30, 2022 | -246.6% | +4082.1 |
| Q3 FY2022CQ2 2022 | Jun 30, 2022 | 213978.5% | +239620.9 |
| Q2 FY2022CQ1 2022 | Mar 31, 2022 | -216776.8% | −218389.2 |
| Q1 FY2022CQ4 2021 | Dec 31, 2021 | 8359.6% | +2283.5 |
| Q4 FY2021CQ3 2021 | Sep 30, 2021 | -4328.7% | −8667.1 |
| Q3 FY2021CQ2 2021 | Jun 30, 2021 | -25642.4% | −37332.2 |
| Q2 FY2021CQ1 2021 | Mar 31, 2021 | 1612.3% | +16478.9 |
| Q1 FY2021CQ4 2020 | Dec 31, 2020 | 6076.1% | −5164.6 |
| Q4 FY2020CQ3 2020 | Sep 30, 2020 | 4338.4% | −2406.3 |
| Q3 FY2020CQ2 2020 | Jun 30, 2020 | 11689.9% | +27752.2 |
| Q2 FY2020CQ1 2020 | Mar 31, 2020 | -14866.5% | −13651.7 |
| Q1 FY2020CQ4 2019 | Dec 31, 2019 | 11240.7% | +10347.2 |
| Q4 FY2019CQ3 2019 | Sep 30, 2019 | 6744.7% | +6852.3 |
| Q3 FY2019CQ2 2019 | Jun 30, 2019 | -16062.3% | −13677.4 |
| Q2 FY2019CQ1 2019 | Mar 31, 2019 | -1214.9% | +1230.8 |
| Q1 FY2019CQ4 2018 | Dec 31, 2018 | 893.6% | – |
| Q3 FY2018CQ2 2018 | Jun 30, 2018 | -107.6% | – |
| Q3 FY2017CQ2 2017 | Jun 30, 2017 | -2384.9% | – |
| Q4 FY2016CQ3 2016 | Sep 30, 2016 | -2445.7% | – |
See a number that looks wrong?